Faisal Zain is a leading authority in medical technology and diagnostics, bringing decades of experience to the complex intersection of patient care and health insurance policy. As a specialist in the manufacturing of medical devices, his work focuses on ensuring that life-sustaining innovations reach the patients who need them most without unnecessary friction. Today, he discusses the systemic challenges of prior authorization and the precarious reality for patients with rare conditions who navigate the shifting landscape of Medicare Advantage.
Our conversation explores the critical breakdown in continuity of care when patients switch insurance providers, the underlying financial motivations that drive coverage denials, and the significant discrepancy between industry promises and the lived experiences of patients. We also look at the resilience required to navigate the medical appeals process and what the future holds for those reliant on high-cost treatments.
What are the primary risks to a patient’s stability when life-sustaining medication is interrupted by a change in insurance providers?
When a patient like Margaret Hvatum, who manages a rare primary immunodeficiency, is forced to stop a treatment like Hizentra, the consequences are immediate and physically devastating. This isn’t just about missing a pill; the medication involves a complex, hands-on process where the patient uses a large syringe and a plastic apparatus—resembling a toy Nerf gun—to drip antibodies into her leg. Without these weekly doses to bolster her immune system, the body becomes a target for infections that a healthy person might easily fight off, such as the urinary tract infection that escalated into a full hospital admission for Margaret. The most frustrating part of this scenario is that the patient’s previous insurer had already approved the care, yet the new carrier, Humana, did not allow that authorization to carry over. This administrative gap turned a 70-year-old marathon runner into a hospital patient within a single month, showing how quickly health can deteriorate when paperwork takes precedence over clinical history.
How does the financial structure of Medicare Advantage plans influence the frequency of medical denials?
The business model of Medicare Advantage is essentially a game of managing margins, where the government pays insurers a fixed monthly sum to cover all care for a member. In 2026, it is estimated that roughly 35 million people will be enrolled in these private policies, and for companies like Humana or UnitedHealth Group, profit is generated when the cost of care is lower than the government’s payment. This creates a powerful incentive to utilize prior authorization as a gatekeeping mechanism; in 2024 alone, these plans reviewed nearly 53 million such requests. While insurers argue that these checks safeguard taxpayer dollars and ensure patient safety, the sheer volume of reviews—averaging nearly two per person enrolled—suggests a system designed to delay spending. For a patient looking at an $8,141.94 bill for a single month of medication, these denials are not just administrative hurdles; they are direct threats to their financial and physical survival.
Why have the recent pledges from major insurers failed to resolve the issues surrounding access to high-cost prescription drugs?
Last summer, following intense public scrutiny, major insurers signed a pledge to reduce the burden of prior authorization, promising to honor existing approvals for a 90-day period when patients switch plans. However, these commitments came with a massive, often overlooked loophole: they applied only to medical services and excluded prescription medications. This distinction is what trapped Margaret in a cycle of denials; while her doctors and previous insurer agreed she needed Hizentra, her new plan viewed the drug as a separate issue from her “medical services.” Even as Humana claims they will remove one-third of prior authorization requirements for outpatient services by July 2025, the exclusion of high-cost biologics means the most vulnerable patients remain at risk. This disconnect between public relations and policy reality leaves patients to navigate a minefield of fine print while their health hangs in the balance.
What does the high success rate of medical appeals tell us about the initial denial process?
The data reveals a startling truth about the current state of healthcare bureaucracy: 81% of Medicare Advantage appeals were partially or fully overturned in 2024. This incredibly high success rate suggests that many initial denials are not based on a lack of medical necessity, but are perhaps issued in the hope that the patient or doctor will not have the stamina to fight back. Margaret’s experience is a perfect example of this persistence; she successfully appealed the denial for her Hizentra, her January hospital stay, and even a hospital stay following a stroke in March. In the latter case, Humana claimed she wasn’t sick enough for a two-night stay despite her having suffered a stroke, only to reverse the decision two weeks after her appeal. The process is designed to be exhausting, and while Margaret had the wherewithal to fight, many patients do not, which ultimately serves the insurer’s bottom line.
How is the emotional and physical toll of these administrative battles changing the way patients view their long-term healthcare options?
For someone like Margaret, who has dedicated her life to health—as seen by the ribbons and trophies hanging like custom drapery in her kitchen—the betrayal by the insurance system is deeply personal. After doing everything possible to stay healthy, including running a full marathon and 5K in the same month, she found herself begging for a medicine she had used for a decade. The sensory details of her life, like the “If found on ground, please drag across the finish line” T-shirt she wears, highlight a level of grit that shouldn’t be required just to get a prescription filled. This frustration is driving people to consider extreme measures; Margaret and her husband are even weighing a move to Norway to access universal healthcare. When a 70-year-old American feels her only path to consistent medical care is to flee the country, it signifies a profound collapse of trust in the domestic healthcare system.
What is your forecast for the future of prior authorization and patient access to specialized medical treatments?
I expect we will see a massive push toward legislative reform as the public and government officials realize that the industry’s self-regulation is insufficient. While we might see more “faster and more seamless” digital processing as Humana has promised, the core conflict between profit and patient access will likely lead to more “gold-carding” laws, where providers with high historical approval rates are exempted from the prior authorization treadmill. However, for high-cost drugs, I predict the battle will only intensify as new, even more expensive biologics hit the market. Patients will increasingly need to act as their own advocates or hire professional navigators to manage the 81% of cases that require an appeal to get the coverage they were promised. Ultimately, if insurers do not begin honoring prior authorizations across plan changes for medications, the “exhausting process” will continue to drive a wedge between patients and their healthcare providers.
